The Biotech Growth Trust in 60 seconds

The Biotech Growth Trust — 2 videos in collection

Edison recently published a review on The Biotech Growth Trust (ticker: BIOG). The trust’s relative performance has been tough during a prolonged drawdown in the biotech industry, due to a focus on smaller-cap companies, whose shares have been particularly weak. However, things are looking brighter as in the five months to the end of August 2025, the trust’s NAV rose by 20%, which its managers hope is just the start of a performance catch up. They acknowledge uncertainties during US president Trump’s second term in office but believe that ultimately very favourable biotech industry fundamentals and attractive valuations will be recognised in the market. Innovation is at an all-time high, the regulatory environment is generally supportive, and M&A activity is likely to accelerate as pharma companies seek to bolster their pipelines in the face of a major patent cliff.

< Previous

You may also be interested in these:

Investment Companies

03.09.24